KR102614574B1 - 릭시세나티드를 이용한 소아 제2형 당뇨병 환자의 치료 - Google Patents

릭시세나티드를 이용한 소아 제2형 당뇨병 환자의 치료 Download PDF

Info

Publication number
KR102614574B1
KR102614574B1 KR1020177022646A KR20177022646A KR102614574B1 KR 102614574 B1 KR102614574 B1 KR 102614574B1 KR 1020177022646 A KR1020177022646 A KR 1020177022646A KR 20177022646 A KR20177022646 A KR 20177022646A KR 102614574 B1 KR102614574 B1 KR 102614574B1
Authority
KR
South Korea
Prior art keywords
treatment
lixisenatide
patient
patients
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177022646A
Other languages
English (en)
Korean (ko)
Other versions
KR20170102550A (ko
Inventor
카린 베르크만
아녜스 엥셀렝-메리
크리스텔 쟌
Original Assignee
사노피-아벤티스 도이칠란트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52354814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102614574(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피-아벤티스 도이칠란트 게엠베하 filed Critical 사노피-아벤티스 도이칠란트 게엠베하
Publication of KR20170102550A publication Critical patent/KR20170102550A/ko
Application granted granted Critical
Publication of KR102614574B1 publication Critical patent/KR102614574B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y10S514/866—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020177022646A 2015-01-16 2016-01-15 릭시세나티드를 이용한 소아 제2형 당뇨병 환자의 치료 Active KR102614574B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15151488.2 2015-01-16
EP15151488 2015-01-16
PCT/EP2016/050804 WO2016113404A1 (en) 2015-01-16 2016-01-15 Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide

Publications (2)

Publication Number Publication Date
KR20170102550A KR20170102550A (ko) 2017-09-11
KR102614574B1 true KR102614574B1 (ko) 2023-12-18

Family

ID=52354814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177022646A Active KR102614574B1 (ko) 2015-01-16 2016-01-15 릭시세나티드를 이용한 소아 제2형 당뇨병 환자의 치료

Country Status (21)

Country Link
US (4) US20160235818A1 (https=)
EP (1) EP3244912B1 (https=)
JP (1) JP7274258B2 (https=)
KR (1) KR102614574B1 (https=)
CN (1) CN107405386A (https=)
AR (1) AR103415A1 (https=)
AU (1) AU2016207964B2 (https=)
CL (1) CL2017001843A1 (https=)
CR (1) CR20170376A (https=)
EA (1) EA035423B1 (https=)
ES (1) ES2895513T3 (https=)
IL (1) IL253460B (https=)
MX (1) MX381944B (https=)
PH (1) PH12017501290A1 (https=)
PL (1) PL3244912T3 (https=)
PT (1) PT3244912T (https=)
SG (1) SG11201705755UA (https=)
TN (1) TN2017000292A1 (https=)
TW (1) TWI706779B (https=)
WO (1) WO2016113404A1 (https=)
ZA (1) ZA201704512B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray
WO2022221172A1 (en) * 2021-04-11 2022-10-20 Khurana Vikas Systems, devices and methods for enacting cyclical positive and negative pressure
WO2024133412A1 (en) 2022-12-21 2024-06-27 Novo Nordisk A/S Methods and systems for estimating fbg value from cgm data

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AR075204A1 (es) * 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EP2435061A4 (en) * 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
PL2324853T3 (pl) * 2009-11-13 2016-01-29 Sanofi Aventis Deutschland Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2707017E (pt) * 2011-05-13 2016-01-12 Sanofi Aventis Deutschland Lixisenatida e metformina para tratamento da diabetes tipo 2
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
AR087693A1 (es) * 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
MX359329B (es) * 2011-10-28 2018-09-25 Sanofi Aventis Deutschland Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov Identifier: NCT01572649*

Also Published As

Publication number Publication date
AU2016207964A1 (en) 2017-08-31
PH12017501290A1 (en) 2018-02-05
TW201639551A (zh) 2016-11-16
JP2018503644A (ja) 2018-02-08
EP3244912A1 (en) 2017-11-22
AR103415A1 (es) 2017-05-10
EA035423B1 (ru) 2020-06-11
IL253460A0 (en) 2017-09-28
US20160235818A1 (en) 2016-08-18
ES2895513T3 (es) 2022-02-21
AU2016207964B2 (en) 2021-10-14
TN2017000292A1 (en) 2019-01-16
NZ734595A (en) 2022-03-25
US20210187075A1 (en) 2021-06-24
ZA201704512B (en) 2019-07-31
TWI706779B (zh) 2020-10-11
CL2017001843A1 (es) 2018-02-23
BR112017015099A2 (pt) 2018-04-17
PT3244912T (pt) 2021-10-27
PL3244912T3 (pl) 2021-12-20
EP3244912B1 (en) 2021-08-18
MX381944B (es) 2025-03-13
EA201791611A1 (ru) 2017-11-30
US20190365864A1 (en) 2019-12-05
CN107405386A (zh) 2017-11-28
US20240173384A1 (en) 2024-05-30
MX2017009294A (es) 2017-11-20
CA2973632A1 (en) 2016-07-21
WO2016113404A1 (en) 2016-07-21
JP7274258B2 (ja) 2023-05-16
IL253460B (en) 2022-06-01
CR20170376A (es) 2017-09-25
KR20170102550A (ko) 2017-09-11
SG11201705755UA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
KR102614574B1 (ko) 릭시세나티드를 이용한 소아 제2형 당뇨병 환자의 치료
US12186374B2 (en) Insulin glargine/lixisenatide fixed ratio formulation
Smith et al. Thrice daily consumption of a novel, premeal shot containing a low dose of whey protein increases time in euglycemia during 7 days of free-living in individuals with type 2 diabetes
Yaw Adu-Sarkodie Clinical management of diabetes mellitus in the older adult patient
JP2022513098A (ja) 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法
Arguelles-Tello et al. Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects
Sertbas et al. Current situation analysis of diabetic home care patients.
CA2973632C (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
Petrova Retrospective analysis of clinical trials of medicinal products for the treatment of diabetes mellitus
BR112017015099B1 (pt) Uso de lixisenatida e/ou um sal farmaceuticamente aceitável da mesma para tratar pacientes pediátricos portadores de diabetes mellitus tipo 2
HK1239556B (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
Moretz Orphan Drug Evaluation: Myalept®(metreleptin) subcutaneous injection
Bakir et al. Novel trends in monitoring and managing diabetes mellitus using electronic nose technology
JP2025518758A (ja) 療法のためのｇｃｇ／ｇｌｐ１コアゴニストを使用する方法
NZ734595B2 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
Shourov A Survey on Prescription Pattern of Diabetes Mellitus
Harris CLINICAL PROTOCOL APPROVAL FORM

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170814

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210113

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230524

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231006

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231212

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231213

End annual number: 3

Start annual number: 1

PG1601 Publication of registration